What are the risks and benefits of hematopoietic stem cell transplantation compared to eculizumab for PNH?

Soliris 300 mg concentrate for solution for infusion. Active Ingredient: eculizumab. Company: Alexion Pharma UK Ltd. See contact details. Soliris is a monoclonal antibody which blocks the complement part of the immune system. It is designed to attach to the C5 protein, which is part of the ... Sep 21, 2024 ... Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and myasthenia gravis. 2. How ... Jun 21, 2024 ... Soliris (eculizumab) is a monoclonal antibody that's approved for patients with atypical hemolytic uremic syndrome (aHUS). It specifically works ... Mar 30, 2022 ... What Are Warnings and Precautions for Eculizumab? · Discontinue if being treated for serious meningococcal infection · Supplement dose with ... What side effects may I notice from receiving this medication? · Back pain · Cough · Diarrhea · Dizziness · Headache · Joint pain · Muscle pain · Nausea ... Why is Soliris authorised in the EU? Soliris was shown to benefit patients with these rare diseases. The safety profile was similar for all the diseases and was ... Feb 15, 2025 ... You will need to receive a meningococcal vaccine at least 2 weeks before you begin your treatment with eculizumab to decrease the risk that you ... Paroxysmal Nocturnal Hemoglobinuria (PNH). SOLIRIS is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce ... What is Eculizumab · It is a monoclonal antibody. · It is used to prevent the breakdown of red blood cells in adults with paroxysmal nocturnal hemoglobinuria (PNH) ...